The Contribution of Postnatal Steroid Administration to Early Brain Damage in Preterm Babies with Bronchopulmonary Dysplasia

Overview

Journal Turk J Med Sci

Specialty General Medicine

Date 2021 Apr 5

PMID 33819976

Citations 3

Authors

Sabahattin Ertugrul

Savas Mert Darakci

Ibrahim Kaplan

Ilyas Yolbas

Ibrahim Deger

Sibel Tanriverdi Yilmaz

Serafettin Aktas

Affiliations

Soon will be listed here.

Abstract

Background/aim: Postnatal corticosteroids are commonly used to treat bronchopulmonary dysplasia (BPD). We aimed to show whether S100 calcium-binding B (S100B), neuron-specific enolase (NSE), Tau protein or microtubule-associated protein tau (MAPT), and glial fibrillary acid protein (GFAP) levels would provide any evidence of early neurological damage in premature infants receiving postnatal low dose dexamethasone therapy for BPD treatment.

Materials And Methods: In this cohort study, 136 preterm infants diagnosed with BPD at ≤32 weeks of gestation formed the study group, and 64 preterm infants formed the control group. NSE, S100B, GFAP, and MAPT levels were first measured before the postnatal corticosteroid treatment in both the patient and the control group on the 28th day and, for a second time, after treatment termination in the patient group.

Results: There were significant differences between the measured GFAP, MAPT, and NSE values of the BPD and control groups on the 28th day, whereas there was no significant difference between the measured S100B values of the two groups. There were a statistically significant difference between the NSE values measured on the 28th day and after the treatment within the BPD group, whereas no significant difference existed between the GFAP, MAPT, and S100B values.

Conclusion: NSE levels, which indicate brain damage in the early period, increased in preterm babies with BPD who had been administered postnatal dexamethasone.

Citing Articles

Prediction of serum neuritin and neuron-specific enolase for prognosis in patients with traumatic brain injury combined with spinal cord injury.

Pu B, Chen Y, Bi Q, Shen J, Wang L, Han Y J Med Biochem. 2025; 43(6):870-878.

PMID: 39876915 PMC: 11771968. DOI: 10.5937/jomb0-45469.

Risk factors and nomogram for the prediction of intracranial hemorrhage in very preterm infants.

Wang Y, Yang Y, Wen L, Li M BMC Pediatr. 2024; 24(1):793.

PMID: 39633312 PMC: 11616105. DOI: 10.1186/s12887-024-05274-0.

Systemic postnatal corticosteroid use for the prevention of bronchopulmonary dysplasia and its relationship to early neurodevelopment in extremely preterm infants.

Esterman E, Goyen T, Jani P, Lowe G, Baird J, Maheshwari R World J Pediatr. 2023; 19(6):586-594.

PMID: 36967444 PMC: 10198830. DOI: 10.1007/s12519-023-00708-8.

No increase in GFAP and S-100B in very preterm infants with mild periventricular leukomalacia or intraventricular hemorrhage: a pilot study.

Koce M, Jerin A, Plut D, Erculj V, Kornhauser Cerar L, Grosek S Croat Med J. 2023; 63(6):564-569.

PMID: 36597568 PMC: 9837718.

References

Catherine R, Vishnu Bhat B, Adhisivam B, Bharadwaj S, Vinayagam V, Chinnakali P . Neuronal Biomarkers in Predicting Neurodevelopmental Outcome in Term Babies with Perinatal Asphyxia. Indian J Pediatr. 2020; 87(10):787-792. DOI: 10.1007/s12098-020-03283-2. View

Celtik C, Acunas B, Oner N, Pala O . Neuron-specific enolase as a marker of the severity and outcome of hypoxic ischemic encephalopathy. Brain Dev. 2004; 26(6):398-402. DOI: 10.1016/j.braindev.2003.12.007. View

Onland W, De Jaegere A, Offringa M, van Kaam A . Systemic corticosteroid regimens for prevention of bronchopulmonary dysplasia in preterm infants. Cochrane Database Syst Rev. 2017; 1:CD010941. PMC: 6464844. DOI: 10.1002/14651858.CD010941.pub2. View

Doyle L, Ehrenkranz R, Halliday H . Dexamethasone treatment in the first week of life for preventing bronchopulmonary dysplasia in preterm infants: a systematic review. Neonatology. 2010; 98(3):217-24. DOI: 10.1159/000286210. View

Doyle L, Halliday H, Ehrenkranz R, Davis P, Sinclair J . An update on the impact of postnatal systemic corticosteroids on mortality and cerebral palsy in preterm infants: effect modification by risk of bronchopulmonary dysplasia. J Pediatr. 2014; 165(6):1258-60. DOI: 10.1016/j.jpeds.2014.07.049. View

Lim G, Lee B, Choi Y, Park H, Chung M, Choi H . Delayed Dexamethasone Therapy and Neurodevelopmental Outcomes in Preterm Infants with Bronchopulmonary Dysplasia. Pediatr Neonatol. 2015; 56(4):261-7. DOI: 10.1016/j.pedneo.2014.11.006. View

Carson R, Monaghan-Nichols A, DeFranco D, Rudine A . Effects of antenatal glucocorticoids on the developing brain. Steroids. 2016; 114:25-32. PMC: 5052110. DOI: 10.1016/j.steroids.2016.05.012. View

Ennen C, Huisman T, Savage W, Northington F, Jennings J, Everett A . Glial fibrillary acidic protein as a biomarker for neonatal hypoxic-ischemic encephalopathy treated with whole-body cooling. Am J Obstet Gynecol. 2011; 205(3):251.e1-7. PMC: 4011017. DOI: 10.1016/j.ajog.2011.06.025. View

Gray P, OCallaghan M, Rogers Y . Psychoeducational outcome at school age of preterm infants with bronchopulmonary dysplasia. J Paediatr Child Health. 2004; 40(3):114-20. DOI: 10.1111/j.1440-1754.2004.00310.x. View

10.

Stoll B, Hansen N, Bell E, Shankaran S, Laptook A, Walsh M . Neonatal outcomes of extremely preterm infants from the NICHD Neonatal Research Network. Pediatrics. 2010; 126(3):443-56. PMC: 2982806. DOI: 10.1542/peds.2009-2959. View

11.

Lv H, Wang Q, Chen H, You Y, Ren P, Li L . Study on serum Tau protein level and neurodevelopmental outcome of placental abruption with neonatal hypoxic-ischemic encephalopathy. J Matern Fetal Neonatal Med. 2019; 33(23):3887-3893. DOI: 10.1080/14767058.2019.1588878. View

12.

Doyle L, Davis P, Morley C, McPhee A, Carlin J . Outcome at 2 years of age of infants from the DART study: a multicenter, international, randomized, controlled trial of low-dose dexamethasone. Pediatrics. 2007; 119(4):716-21. DOI: 10.1542/peds.2006-2806. View

13.

Leon-Lozano M, Arnaez J, Valls A, Arca G, Agut T, Alarcon A . Cerebrospinal fluid levels of neuron-specific enolase predict the severity of brain damage in newborns with neonatal hypoxic-ischemic encephalopathy treated with hypothermia. PLoS One. 2020; 15(6):e0234082. PMC: 7263594. DOI: 10.1371/journal.pone.0234082. View

14.

Sun J, Li J, Cheng G, Sha B, Zhou W . Effects of hypothermia on NSE and S-100 protein levels in CSF in neonates following hypoxic/ischaemic brain damage. Acta Paediatr. 2012; 101(8):e316-20. DOI: 10.1111/j.1651-2227.2012.02679.x. View

15.

Jarjour I . Neurodevelopmental outcome after extreme prematurity: a review of the literature. Pediatr Neurol. 2014; 52(2):143-52. DOI: 10.1016/j.pediatrneurol.2014.10.027. View

16.

Filippone M, Nardo D, Bonadies L, Salvadori S, Baraldi E . Update on Postnatal Corticosteroids to Prevent or Treat Bronchopulmonary Dysplasia. Am J Perinatol. 2019; 36(S 02):S58-S62. DOI: 10.1055/s-0039-1691802. View

17.

Summanen M, Seikku L, Rahkonen P, Stefanovic V, Teramo K, Andersson S . Comparison of Umbilical Serum Copeptin Relative to Erythropoietin and S100B as Asphyxia Biomarkers at Birth. Neonatology. 2017; 112(1):60-66. DOI: 10.1159/000456063. View

18.

Florio P, Abella R, Marinoni E, Di Iorio R, Volti G, Galvano F . Biochemical markers of perinatal brain damage. Front Biosci (Schol Ed). 2009; 2(1):47-72. DOI: 10.2741/s45. View

19.

Garcia-Alix A, Cabanas F, Pellicer A, Hernanz A, Stiris T, Quero J . Neuron-specific enolase and myelin basic protein: relationship of cerebrospinal fluid concentrations to the neurologic condition of asphyxiated full-term infants. Pediatrics. 1994; 93(2):234-40. View

20.

Qin G, Lo J, Marlow N, Calvert S, Greenough A, Peacock J . Postnatal dexamethasone, respiratory and neurodevelopmental outcomes at two years in babies born extremely preterm. PLoS One. 2017; 12(7):e0181176. PMC: 5517008. DOI: 10.1371/journal.pone.0181176. View